ARTIMPLANT INTERIM REPORT JANUARY – SEPTEMBER 2008

Västra Frölunda, Sweden, November 11, 2008

• Net revenue for the third quarter amounted to SEK 2.3 million (2.6) and for January-September to SEK 7.5 million (11.2)*
• The net loss for the third quarter totaled SEK 4.3 million (3.6) and for January-September SEK 16.6 million (11.3)
• Earnings per share for the third quarter amounted to SEK -0.07 (-0.06) and for January-September to SEK -0.28 (-0.19)
• Sales of Artelon® Spacer to end-customers totaled approximately 2,600 (2,800) units, of which 1,000 (700) were during the third quarter
• Sales of Artelon® Tissue Reinforcement to end-customers totaled approximately 700 (400) units, of which 300 (150) were during the third quarter
• Over 10,000 patients have been treated with Artelon® implants up to and including September 2008

Events after the period-end
• The first patients were treated in a US-based study for treatment of rotator cuff tears
• The nomination committee was formed
o Anders Algotsson, AFA Insurances
o John Arnold, J&C Arnold Revocable Trust
o Sven Zetterqvist, The Life Insurance Company Skandia
o Ingemar Kihlström, Chairman Artimplant AB

N.B. This is a translation from Swedish. The Swedish version shall always take precedence.

Artimplant will hold a telephone conference by reason of this report on November 11, 2008 at 11 am (GMT+1). For further information see www.artimplant.com.

* Figures in brackets refer to the corresponding period last year